Akèy › Kansè Poumon ki pa ti selil › Washington › Tacoma
Etid klinik pou Kansè Poumon ki pa ti selil nan Tacoma, WA
20 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Tacoma (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Ap rekriteFaz 3
- Northwest Medical Specialties - Tacoma, Tacoma
- Northwest Medical Specialties - Gig Harbor, Gig Harbor · 8 mi lwen
- Northwest Medical Specialties - Puyallup Medical Oncology, Puyallup · 8 mi lwen
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Ap rekriteFaz 1/2
- Northwest Medical Specialties Tacoma /ID# 270469, Tacoma
- Vista Oncology - East Olympia /ID# 275438, Olympia · 26 mi lwen
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- American Oncology Network Vista Oncology Division-West office, Olympia · 26 mi lwen
- American Oncology Network Vista Oncology Division-East office, Olympia · 26 mi lwen
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Ap rekriteFaz 3
- Vista Oncology Inc PS, Olympia · 26 mi lwen
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Ap rekriteFaz 3
- American Oncology Network Vista Oncology Division-West office, Olympia · 26 mi lwen
- American Oncology Network Vista Oncology Division-East office, Olympia · 26 mi lwen
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Vista Oncology, Olympia · 26 mi lwen
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
- Northwest Medical Specialties, Tacoma
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- Northwest Medical Specialties (NWMS), Tacoma
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Ap rekriteFaz 3
- Local Institution - 0499, Lacey · 23 mi lwen
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Tacoma
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Northwest Medical Specialties Tacoma /ID# 270534, Tacoma
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Research Site, Tacoma
- Research Site, Olympia · 26 mi lwen
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2/3
- Vista Oncology - East Olympia /ID# 262303, Olympia · 26 mi lwen
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Tacoma
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- Northwest Medical Specialties, Tacoma
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Tacoma
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Ap rekriteFaz 1
- Exigent Research, LLC, Tacoma
- Northwest Medical Specialities, PLLC, Tacoma
- Northwest Medical Specialities. PLLC, Gig Harbor · 8 mi lwen
- ak 3 plis
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Ap rekriteFaz 3
- MultiCare Institute for Research & Innovation, Tacoma
- MultiCare Regional Cancer Center, Gig Harbor · 8 mi lwen
- MultiCare Regional Cancer Center, Puyallup · 8 mi lwen
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
- USA09-0, Puyallup · 8 mi lwen
BostonGene and Exigent Genomic INsight Study
Ap rekriteEtid obsèvasyon
- Northwest Medical Specialities, Puyallup · 8 mi lwen
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY120 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH56 etid
- Washington, DC55 etid
Lòt etid nan Tacoma
- Kansè nan tete18 etid
- Kolit Ulseratif15 etid
- Myelom Miltip13 etid
- Kansè pwostat11 etid
- Maladi Crohn11 etid
- Kansè Metastatik9 etid
- Kansè kolorektal9 etid
- Melanom7 etid
- Kansè ovè7 etid
- Kansè (tout kalite)6 etid
- Kansè pankreyas6 etid
- Obèsite6 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.